Almirall underwhelms again but reiterates 2022 guidance

25 July 2022

Spanish dermatology specialist Almirall (BME: ALM) was trading 4.8% lower mid-afternoon on Monday after the presentation of its latest financial results.

Although core net sales were up by 5% at 436.6 million euros ($447.4 million) for the first half of 2022, Almirall missed analyst expectations with its earnings before interest, taxes, depreciation and amortization (EBITDA) figures.

Total EBITDA was 107.6 million euros, a 21% drop compared to the first half of 2021. This was blamed on product divestments in the previous year and the finalization of deferred income from AstraZeneca (LSE: AZN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK